Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study

Abstract

HER2 expression is correlated with diminished efficacy of Bacillus Calmette–Guérin (BCG) instillation in high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The development of effective intravesical treatments for HER2-expressing HR-NMIBC is of great urgency. In this single-arm phase I trial (ChiCTR2300073975), HER2-expressing HR-NMIBC patients received an induction course of weekly intravesical Disitamab vedotin (RC48) following a 3+3 design (60, 120, or 180 mg) for 6 weeks, followed by optional maintenance dose monthly for 11 sessions. The primary objective was to assess the safety and tolerability of intravesical RC48. The secondary objective was to determine the oncological outcomes. Between August 2023 and March 2024, nine patients were enrolled, and all completed the induction course without dose-limiting toxicities (DLTs) or grade ≥3 drug-related adverse events (AEs). The reported drug-related AEs included urinary tract infection (55.6%, 5/9), urinary frequency (11.1%, 1/9), and hematuria (11.1%, 1/9). The 6-month and 12-month recurrence-free survival (RFS) rates were 100% (8/8) and 87.5% (7/8), respectively, whereas the progression-free survival (PFS) rates were 100% (8/8) and 100% (8/8). Taken together, these findings indicate that intravesical RC48 was well tolerated and showed preliminary efficacy in HER2-expressing HR-NMIBC. The maximum tolerated dose was not reached, and further dose exploration is ongoing (NCT06378242).

Keywords

antibody‒drug conjugates (ADC) / Disitamab vedotin (RC48) / efficacy / intravesical / non-muscle-invasive bladder cancer / safety

References

[1] Safiri S, Kolahi AA, Naghavi M, “Global,” BMJ Global Health 6, no. 11 (2021): e004128.

[2] Sung H, Ferlay J, Siegel RL, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: a Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[3] van Straten C, Bruins MH, Dijkstra S, et al., “The Accuracy of Cystoscopy in Predicting Muscle Invasion in Newly Diagnosed Bladder Cancer Patients,” World Journal of Urology 41, no. 7 (2023): 1829-1835.

[4] Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L, “Advances in Diagnosis and Treatment of Bladder Cancer,” BMJ (Clinical Research Ed) 384 (2024): e076743.

[5] Tan X, Liu Z, Cai T, et al., “Prognostic Significance of HER2 Expression in Patients With Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer,” European Urology Oncology 7, no. 4 (2024): 760-769.

[6] Hong X, Chen X, Wang H, et al., “A HER2-Targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety With Intravesical Instillation in Preclinical Models of Bladder Cancer,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 10, no. 32 (2023): e2302377.

[7] Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H, “HER2-Targeted Therapies in Cancer: A Systematic Review,” Biomarker Research 12, no. 1 (2024): 16.

[8] Sanguedolce F, Zanelli M, Palicelli A, et al., “HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role,” International Journal of Molecular Sciences 24, no. 4 (2023): 3720.

[9] Hussain MH, MacVicar GR, Petrylak DP, et al., “Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/Neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25, no. 16 (2007): 2218-2224.

[10] Balar AV, Kamat AM, Kulkarni GS, et al., “Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study,” Lancet Oncology 22, no. 7 (2021): 919-930.

[11] Burke JM, Lamm DL, Meng MV, et al., “A First in human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer,” Journal of Urology 188, no. 6 (2012): 2391-2397.

[12] Al Hussein Al Awamlh B, Chang SS, “Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer,” Current Oncology Reports 25, no. 2 (2023): 83-91.

[13] Sheng X, Wang L, He Z, et al., “Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 42, no. 12 (2024): 1391-402.

[14] Li L, Xu MZ, Wang L, et al., “Conjugating MMAE to a Novel Anti-HER2 Antibody for Selective Targeted Delivery,” European Review for Medical and Pharmacological Sciences 24, no. 24 (2020): 12929-12937.

[15] de Jong FC, Laajala TD, Hoedemaeker RF, et al., “Non-Muscle-Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin,” Science Translational Medicine 15, no. 697 (2023): eabn4118.

[16] Sheng X, Zhang C, Ji Y, et al., “Neoadjuvant Treatment With Disitamab Vedotin Plus Perioperative Toripalimab in Patients With Muscle-Invasive Bladder Cancer (MIBC) With HER2 Expression: Updated Efficacy and Safety Results From the Phase II RC48-C017 Trial,” Journal of Clinical Oncology 43, no. 5 (2025): 665.

[17] Padua TC, Moschini M, Martini A, et al., “Efficacy and Toxicity of Antibody-Drug Conjugates in the Treatment of Metastatic Urothelial Cancer: A Scoping Review,” Urologic Oncology 40, no. 10 (2022): 413-423.

[18] Lu JL, Xia QD, Liu CQ, et al., “Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacille Calmette-Guérin for Ta and T1 Bladder Cancer: A Systematic Review and Meta-Analysis,” Translational Cancer Research 10, no. 6 (2021): 2849-2858.

[19] Kirschner AN, Wang J, Rajkumar-Calkins A, Neuzil KE, Chang SS, “Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model,” Journal of Urology 205, no. 5 (2021): 1336-1343.

[20] Zugail AS, Pinar U, Irani J, “Evaluation of Pain and Catheter-related Bladder Discomfort Relative to Balloon Volumes of Indwelling Urinary Catheters: A Prospective Study,” Investigative and Clinical Urology 60, no. 1 (2019): 35-39.

[21] Meghani K, Cooley LF, Choy B, et al., “First-in-Human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin,” European Urology 82, no. 6 (2022): 602-610.

[22] Patel SH, Gabrielson AT, Chan S, et al., “A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder,” Journal of Urology 212, no. 1 (2024): 95-103.

[23] Longoni M, Scilipoti P, Soria F, et al., “Oncological Outcomes in Bacillus Calmette-Guérin-Naïve High-Risk Non-Muscle-Invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives,” European Urology Oncology (2025): S2588-9311(25)00081-1.

[24] Boorjian SA, Alemozaffar M, Konety BR, et al., “Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Repeat-Dose Clinical Trial,” Lancet Oncology 22, no. 1 (2021): 107-117.

[25] Heijden MSVD, Cutie C, Hampras S, et al., “SunRISe-1: Phase 2b Study of TAR-200 Plus Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Nonmuscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin Who Are Ineligible for or Decline Radical Cystectomy,” Journal of Clinical Oncology 40, no. 6 (2022): TPS593-TPS593.

[26] Lei H, Ling Y, Yuan P, et al., “Assessment of the Expression Pattern of HER2 and Its Correlation With HER2-Targeting Antibody-Drug Conjugate Therapy in Urothelial Cancer,” Journal of the National Cancer Center 3, no. 2 (2023): 121-128.

[27] Yan X, Li J, Xu H, et al., “Efficacy and Safety of DV in HER2-Negative and HER2-Low Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Phase 2 Study,” Med (New York, NY) (2025): 100637.

[28] Wang J, Liu Y, Zhang Q, et al., “Disitamab Vedotin, a HER2-Directed Antibody-Drug Conjugate, in Patients With HER2-Overexpression and HER2-Low Advanced Breast Cancer: A Phase I/Ib Study,” Cancer Communications 44, no. 7 (2024): 833-851.

[29] Ruan W, Chen X, Huang M, et al., “A Urine-Based DNA Methylation Assay to Facilitate Early Detection and Risk Stratification of Bladder Cancer,” Clinical Epigenetics 13, no. 1 (2021): 91.

[30] Chen X, Zhang J, Ruan W, et al., “Urine DNA Methylation Assay Enables Early Detection and Recurrence Monitoring for Bladder Cancer,” Journal of Clinical Investigation 130, no. 12 (2020): 6278-6289.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.